Editor's note: Seeking Alpha is proud to welcome Nicholas Pugliese as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
Last week, Biogen (BIIB) and partner Eisai (ESALY) announced the termination of studies involving Aducanumab, a monoclonal antibody targeting amyloid-beta protein fibers that are a hallmark of Alzheimer's Disease. The two announced that they would be terminating the study as an interim analysis